Log in with your email address username.

×

Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Department of Error] Department of Error

Connolly SJ, Eikelboom JW, Bosch J, et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 2017; 391: 205–18—In this Article (published online first on Nov 10, 2017) the TIMI score was calculated incorrectly, without the use of all nine factors that made up the score, which resulted in changes to the composite primary outcome described in the text and shown in figure 4. There were also a few GUSTO bleeds that qualified in one of the categories, which resulted in changes to table 3.

email